CBIO

SEC source: 0001104659-25-119320 · tm2532982-1_4seq1.xml · nonDerivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Fairmount Healthcare Fund II L.P.

Disclosed balance after: 2,747,866

F1 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-25-068426 · tm2521104-1_4seq1.xml · derivative · entry 1

Pinkas Jan · CIK 0002077126 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,474

Underlying: Ordinary Shares · 142,474 shares

Expires 2035-07-16

F1 · derivative.exercise_date: This option will vest as to 25% on July 7, 2026 and in equal monthly installments thereafter through July 7, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC source: 0001104659-25-061817 · tm2518376-14_4seq1.xml · derivative · entry 1

Balcom Alexandra · CIK 0001862147 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,023

Underlying: Ordinary Shares · 9,023 shares

Expires 2035-06-23

F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-061820 · tm2518376-18_4seq1.xml · derivative · entry 1

Moran Susan · CIK 0001835225 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,023

Underlying: Ordinary Shares · 9,023 shares

Expires 2035-06-23

F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-061819 · tm2518376-17_4seq1.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Peter Harwin

Disclosed balance after: 9,023

Underlying: Ordinary Shares · 9,023 shares

Expires 2035-06-23

F1 · derivative.exercise_date: This option represents a right to purchase 9,023 of the Issuer's ordinary shares, which vest in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

F2 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ("Fairmount"), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or shares received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying ordinary shares. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-25-061818 · tm2518376-15_4seq1.xml · derivative · entry 1

Violin Jonathan · CIK 0001730615 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,023

Underlying: Ordinary Shares · 9,023 shares

Expires 2035-06-23

F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-061816 · tm2518376-13_4seq1.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,023

Underlying: Ordinary Shares · 9,023 shares

Expires 2035-06-23

F1 · derivative.exercise_date: This option represents a right to purchase shares of the Issuer's ordinary shares and vests in full on the earlier of (i) June 23, 2026 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0000921895-25-001784 · form407422010_06172025.xml · derivative · entry 6

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner

BVF I GP LLC · CIK 0001803805 · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,944

Underlying: Common Stock · 25,944 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F6 · derivative.exercise_price: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F5 · kind: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F5 · price: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F6 · derivative.exercise_date: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F6 · derivative.expiration_date: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F7 · balance_after: Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-25-001784 · form407422010_06172025.xml · derivative · entry 5

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner

BVF I GP LLC · CIK 0001803805 · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 257,515

Underlying: Common Stock · 257,515 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F6 · derivative.exercise_price: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F5 · kind: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F5 · price: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F6 · derivative.exercise_date: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F6 · derivative.expiration_date: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F7 · balance_after: Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-25-001784 · form407422010_06172025.xml · derivative · entry 4

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner

BVF I GP LLC · CIK 0001803805 · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,098

Underlying: Common Stock · 304,098 shares

Expires not disclosed

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F6 · derivative.exercise_price: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F5 · kind: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F5 · price: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F6 · derivative.exercise_date: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F6 · derivative.expiration_date: Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise, the holder (together with its attribution parties) would own more than 9.99% of the shares of Common Stock outstanding immediately after such exercise. The exercise price of the Pre-Funded Warrants is equal to $0.001 divided by 0.1445.

F7 · balance_after: Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000921895-25-001784 · form407422010_06172025.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner

BVF I GP LLC · CIK 0001803805 · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,383

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · kind: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F5 · price: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F7 · balance_after: Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-25-001784 · form407422010_06172025.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner

BVF I GP LLC · CIK 0001803805 · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 593,740

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · kind: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F5 · price: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F7 · balance_after: Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.

SEC source: 0000921895-25-001784 · form407422010_06172025.xml · nonDerivative · entry 1

BVF PARTNERS L P/IL · CIK 0001055947 · 10% owner

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · 10% owner

BVF I GP LLC · CIK 0001803805 · 10% owner

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · 10% owner

BVF INC/IL · CIK 0001056807 · 10% owner

LAMPERT MARK N · CIK 0001233840 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 707,116

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously collectively owned more than 10% of the Issuer's outstanding shares of Common Stock (the "Common Stock"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F5 · kind: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F5 · price: On June 13, 2025, the Issuer completed a reverse merger transaction (the "Merger") with Crescent Biopharma, Inc. pursuant to that certain Agreement and Plan of Merger and Reorganization, dated October 28, 2024, as amended by Amendment No. 1 to the Agreement and Plan of Merger and Reorganization, dated February 14, 2025. In connection with the Merger, the Reporting Persons acquired an aggregate of 1,292,422 shares of Common Stock and 597,928 pre-funded warrants to purchase shares of Common Stock (the "Pre-Funded Warrants"), in exchange for all of the former Crescent Biopharma, Inc. capital stock owned by the Reporting Persons.

F7 · balance_after: Represents the number of securities owned following the Issuer's 1-for-100 Reverse Stock Split effected immediately prior to the Merger.

F2 · ownership.direct: Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.

SEC source: 0000950170-24-094800 · ownership.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,317,565

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-094800 · ownership.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,578,438

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-092864 · ownership.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,639,926

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1907 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-092864 · ownership.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,695,658

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.187 to $0.1891 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-090910 · ownership.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,860,181

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.20 to $0.2025 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-090910 · ownership.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,146,381

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.2185 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-088020 · ownership.xml · nonDerivative · entry 3

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,209,945

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.215 to $0.24 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-088020 · ownership.xml · nonDerivative · entry 2

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,966,780

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.23 to $0.241 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0000950170-24-088020 · ownership.xml · nonDerivative · entry 1

Invus Public Equities, L.P. · CIK 0001340097 · 10% owner

Invus Public Equities Advisors, LLC · CIK 0001340096 · 10% owner

Siren, L.L.C. · CIK 0002005245 · 10% owner

Invus Global Management, LLC · CIK 0002005369 · 10% owner

DEBBANE RAYMOND · CIK 0001053890 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,330,729

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.24 to $0.2451 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · ownership.direct: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.

F2 · ownership.direct: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC source: 0001415889-24-017978 · form4-06242024_080643.xml · nonDerivative · entry 2

Rock Edwin · CIK 0001945417 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 680,403

F2 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2579 to $0.27 per share, with a weighted average purchase price of $0.2671 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001415889-24-017978 · form4-06242024_080643.xml · nonDerivative · entry 1

Rock Edwin · CIK 0001945417 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,403

F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.24 to $0.2594 per share, with a weighted average purchase price of $0.2532 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001415889-24-017623 · form4-06202024_040634.xml · nonDerivative · entry 1

Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,643

F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $0.2453 to $0.2478 per share, with a weighted average purchase price of $0.2477 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001415889-24-011860 · form4-05012024_080522.xml · derivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-011862 · form4-05012024_080551.xml · derivative · entry 1

Andrews Patricia S · CIK 0001445710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-011872 · form4-05012024_080541.xml · derivative · entry 1

Koenig Scott · CIK 0001587514 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-011869 · form4-05012024_080555.xml · derivative · entry 1

Goldberg Mark Alan · CIK 0001532475 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-011867 · form4-05012024_080504.xml · derivative · entry 1

PEARSON TIMOTHY R · CIK 0001528617 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-011863 · form4-05012024_080549.xml · derivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-011861 · form4-05012024_080513.xml · derivative · entry 1

Jackson Scott Thomas · CIK 0001566617 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2034-04-30

F1 · derivative.exercise_date: The shares underlying this option vest on May 1, 2025, subject to the reporting person's continuous service as of such vesting date.

SEC source: 0001415889-24-009745 · form4-04022024_040420.xml · nonDerivative · entry 1

JUNIUS DANIEL M · CIK 0001094159 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,459

F1 · shares: These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $15,625.

SEC source: 0001415889-24-009743 · form4-04022024_040411.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 515,194

F1 · shares: These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $10,000.

SEC source: 0001415889-24-009744 · form4-04022024_040413.xml · nonDerivative · entry 1

Goldberg Mark Alan · CIK 0001532475 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,828

F1 · shares: These shares will be issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750.

SEC source: 0001209191-24-001741 · doc4.xml · derivative · entry 1

Semerjian Harout · CIK 0001809747 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 695,000

Underlying: Common Stock · 695,000 shares

Expires 2034-01-11

F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-24-001742 · doc4.xml · derivative · entry 1

Johnson Bruce S · CIK 0001971197 · SVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-01-11

F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-24-001740 · doc4.xml · derivative · entry 1

Rock Edwin · CIK 0001945417 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-01-11

F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-24-001739 · doc4.xml · derivative · entry 1

Rath Chinmaya · CIK 0001969660 · SVP and Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-01-11

F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-24-001738 · doc4.xml · derivative · entry 1

Hahn Brian M. · CIK 0001589711 · SVP Finance, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-01-11

F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 12, 2025 and the remaining shares will vest in equal monthly installments over 36 months thereafter, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-24-000069 · doc4.xml · nonDerivative · entry 1

Andrews Patricia S · CIK 0001445710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,608

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $12,250.

SEC source: 0001209191-24-000068 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 511,860

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $10,000.

SEC source: 0001209191-24-000067 · doc4.xml · nonDerivative · entry 1

Goldberg Mark Alan · CIK 0001532475 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,244

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750.

SEC source: 0001209191-23-051392 · doc4.xml · nonDerivative · entry 1

Andrews Patricia S · CIK 0001445710 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,417

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $12,250.

SEC source: 0001209191-23-051449 · doc4.xml · nonDerivative · entry 1

Goldberg Mark Alan · CIK 0001532475 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,417

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board and committee retainer fees of $13,750.

SEC source: 0001209191-23-051390 · doc4.xml · nonDerivative · entry 1

King Rachel K. · CIK 0001589712 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 507,622

F1 · shares: These shares were issued to the reporting person pursuant to the issuer's non-employee director compensation policy in lieu of board retainer fees of $10,000.

SEC source: 0001209191-23-050476 · doc4.xml · nonDerivative · entry 2

Rock Edwin · CIK 0001945417 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 375,403

F2 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.37 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-23-050476 · doc4.xml · nonDerivative · entry 1

Rock Edwin · CIK 0001945417 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,000

F1 · price: The Reporting Person purchased the securities on the open market at purchase prices ranging from $1.35 to $1.40 per share, with a weighted average purchase price of $1.38 per share. The Reporting Person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001209191-23-033675 · doc4.xml · derivative · entry 2

Koenig Scott · CIK 0001587514 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,000 shares

Expires 2032-05-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares underlying this option vested on May 18, 2023 and are fully exercisable.

SEC source: 0001209191-23-033675 · doc4.xml · nonDerivative · entry 1

Koenig Scott · CIK 0001587514 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.